DOCSLIB.ORG

Supplemental Table S1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplemental Table S1 Entrez Gene Symbol Gene Name Affymetrix EST Glomchip SAGE Stanford Literature HPA confirmed Gene ID Profiling profiling Profiling Profiling array profiling confirmed 1 2 A2M alpha-2-macroglobulin 0 0 0 1 0 2 10347 ABCA7 ATP-binding cassette, sub-family A (ABC1), member 7 1 0 0 0 0 3 10350 ABCA9 ATP-binding cassette, sub-family A (ABC1), member 9 1 0 0 0 0 4 10057 ABCC5 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 1 0 0 0 0 5 10060 ABCC9 ATP-binding cassette, sub-family C (CFTR/MRP), member 9 1 0 0 0 0 6 79575 ABHD8 abhydrolase domain containing 8 1 0 0 0 0 7 51225 ABI3 ABI gene family, member 3 1 0 1 0 0 8 29 ABR active BCR-related gene 1 0 0 0 0 9 25841 ABTB2 ankyrin repeat and BTB (POZ) domain containing 2 1 0 1 0 0 10 30 ACAA1 acetyl-Coenzyme A acyltransferase 1 (peroxisomal 3-oxoacyl-Coenzyme A thiol 0 1 0 0 0 11 43 ACHE acetylcholinesterase (Yt blood group) 1 0 0 0 0 12 58 ACTA1 actin, alpha 1, skeletal muscle 0 1 0 0 0 13 60 ACTB actin, beta 01000 1 14 71 ACTG1 actin, gamma 1 0 1 0 0 0 15 81 ACTN4 actinin, alpha 4 0 0 1 1 1 10700177 16 10096 ACTR3 ARP3 actin-related protein 3 homolog (yeast) 0 1 0 0 0 17 94 ACVRL1 activin A receptor type II-like 1 1 0 1 0 0 18 8038 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 1 0 0 0 0 19 8751 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 1 0 0 0 0 20 8728 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 1 0 0 0 0 21 81792 ADAMTS12 ADAM metallopeptidase with thrombospondin type 1 motif, 12 1 0 0 0 0 22 9507 ADAMTS4 ADAM metallopeptidase with thrombospondin type 1 motif, 4 0 0 1 0 0 23 11096 ADAMTS5 ADAM metallopeptidase with thrombospondin type 1 motif, 5 (aggrecanase-2) 1 0 1 0 0 24 56999 ADAMTS9 ADAM metallopeptidase with thrombospondin type 1 motif, 9 0 0 0 0 1 25 107 ADCY1 adenylate cyclase 1 (brain) 1 0 1 0 0 26 196883 ADCY4 adenylate cyclase 4 1 0 1 0 0 27 120 ADD3 adducin 3 (gamma) 0 0 0 1 0 28 133 ADM adrenomedullin 1 0 0 0 0 9564831 29 165 AEBP1 AE binding protein 1 1 0 0 0 0 30 166 AES amino-terminal enhancer of split 0 0 0 1 0 31 84632 AFAP1L2 actin filament associated protein 1-like 2 1 0 0 0 0 32 177 AGER advanced glycosylation end product-specific receptor 1 0 1 0 0 12651605 33 56895 AGPAT4 1-acylglycerol-3-phosphate O-acyltransferase 4 (lysophosphatidic acid acyltrans 10100 34 187 AGTRL1 angiotensin II receptor-like 1 0 0 0 1 1 35 79026 AHNAK AHNAK nucleoprotein (desmoyokin) 0 1 0 1 0 36 199 AIF1 allograft inflammatory factor 1 0 0 0 1 1 37 203 AK1 adenylate kinase 1 1 0 1 0 0 38 9590 AKAP12 A kinase (PRKA) anchor protein (gravin) 12 1 0 0 0 0 39 10142 AKAP9 A kinase (PRKA) anchor protein (yotiao) 9 0 0 1 0 0 40 10327 AKR1A1 aldo-keto reductase family 1, member A1 (aldehyde reductase) 0 1 0 0 0 41 208 AKT2 v-akt murine thymoma viral oncogene homolog 2 1 0 0 0 0 42 10000 AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) 1 0 0 0 0 43 239 ALOX12 arachidonate 12-lipoxygenase 1 0 0 0 0 44 259173 ALS2CL ALS2 C-terminal like 0 0 0 0 1 45 154810 AMOTL1 angiomotin like 1 1 0 0 0 0 46 64682 ANAPC1 anaphase promoting complex subunit 1 0 1 0 0 0 47 23452 ANGPTL2 angiopoietin-like 2 1 1 1 0 0 48 29123 ANKRD11 ankyrin repeat domain 11 1 0 0 0 0 49 163782 ANKRD38 ankyrin repeat domain 38 1 1 0 0 0 50 91526 ANKRD44 ankyrin repeat domain 44 1 0 0 0 0 51 256949 ANKRD47 ankyrin repeat domain 47 1 0 0 0 0 52 57182 ANKRD50 ankyrin repeat domain 50 1 0 0 0 0 53 22881 ANKRD6 ankyrin repeat domain 6 1 0 0 0 0 54 301 ANXA1 annexin A1 10010 55 302 ANXA2 annexin A2 1 1 1 1 0 16249193 56 306 ANXA3 annexin A3 10100 57 308 ANXA5 annexin A5 0 1 0 0 0 11271515 58 8905 AP1S2 adaptor-related protein complex 1, sigma 2 subunit 0 0 0 0 1 59 323 APBB2 amyloid beta (A4) precursor protein-binding, family B, member 2 (Fe65-like) 1 0 0 0 0 60 333 APLP1 amyloid beta (A4) precursor-like protein 1 1 0 0 0 1 61 347 APOD apolipoprotein D 0 0 0 1 0 62 81575 APOLD1 apolipoprotein L domain containing 1 0 0 1 0 0 63 375 ARF1 ADP-ribosylation factor 1 0 1 0 0 0 14684384 64 79822 ARHGAP28 Rho GTPase activating protein 28 1 0 0 0 1 65 55160 ARHGEF10L Rho guanine nucleotide exchange factor (GEF) 10-like 0 1 0 0 0 66 23365 ARHGEF12 Rho guanine nucleotide exchange factor (GEF) 12 1 0 0 0 0 67 9828 ARHGEF17 Rho guanine nucleotide exchange factor (GEF) 17 1 0 0 0 0 68 23370 ARHGEF18 rho/rac guanine nucleotide exchange factor (GEF) 18 1 0 0 0 0 69 50650 ARHGEF3 Rho guanine nucleotide exchange factor (GEF) 3 1 0 0 0 0 70 9459 ARHGEF6 Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 1 0 0 0 0 1 71 10865 ARID5A AT rich interactive domain 5A (MRF1-like) 1 0 0 0 0 72 84159 ARID5B AT rich interactive domain 5B (MRF1-like) 0 0 1 0 0 73 200894 ARL13B ADP-ribosylation factor-like 13B 0 1 0 0 0 74 23204 ARL6IP1 ADP-ribosylation factor-like 6 interacting protein 1 0 1 0 0 0 75 10550 ARL6IP5 ADP-ribosylation-like factor 6 interacting protein 5 0 0 1 0 0 76 219681 ARMC3 armadillo repeat containing 3 1 0 0 0 0 77 51309 ARMCX1 armadillo repeat containing, X-linked 1 1 0 0 0 0 78 158947 ARMCX4 armadillo repeat containing, X-linked 4 1 0 0 0 0 79 10095 ARPC1B actin related protein 2/3 complex, subunit 1B, 41kDa 1 0 0 0 0 80 10109 ARPC2 actin related protein 2/3 complex, subunit 2, 34kDa 0 1 1 0 0 81 10093 ARPC4 actin related protein 2/3 complex, subunit 4, 20kDa 0 1 0 0 0 82 408 ARRB1 arrestin, beta 1 1 0 0 0 0 1 83 419 ART3 ADP-ribosyltransferase 3 1 0 1 0 0 84 421 ARVCF armadillo repeat gene deletes in velocardiofacial syndrome 1 0 1 0 0 85 340485 ASAH3L N-acylsphingosine amidohydrolase 3-like 1 0 0 0 0 86 23020 ASCC3L1 activating signal cointegrator 1 complex subunit 3-like 1 0 1 0 0 0 87 25842 ASF1A ASF1 anti-silencing function 1 homolog A (S. cerevisiae) 0 0 1 0 0 88 460 ASTN1 astrotactin 1 10000 89 468 ATF4 activating transcription factor 4 (tax-responsive enhancer element B67) 0 1 0 0 0 90 57194 ATP10A ATPase, Class V, type 10A 0 0 0 0 1 91 57205 ATP10D ATPase, Class V, type 10D 1 0 0 0 0 92 482 ATP1B2 ATPase, Na+/K+ transporting, beta 2 polypeptide 1 0 0 0 0 93 489 ATP2A3 ATPase, Ca++ transporting, ubiquitous 1 0 0 0 0 94 8992 ATP6V0E1 ATPase, H+ transporting, lysosomal 9kDa, V0 subunit e1 0 1 0 0 0 95 9550 ATP6V1G1 ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G1 0 1 0 1 0 96 10396 ATP8A1 ATPase, aminophospholipid transporter (APLT), Class I, type 8A, member 1 1 1 0 0 1 97 8455 ATRN attractin 00100 98 26033 ATRNL1 attractin-like 1 01000 99 6311 ATXN2 ataxin 2 00010 100 558 AXL AXL receptor tyrosine kinase 1 0 0 0 0 101 79888 AYTL2 acyltransferase like 2 1 0 0 0 0 102 567 B2M beta-2-microglobulin 0 1 0 1 0 103 145173 B3GALTL beta 1,3-galactosyltransferase-like 0 1 0 0 0 104 60468 BACH2 BTB and CNC homology 1, basic leucine zipper transcription factor 2 0 0 0 1 0 105 4059 BCAM basal cell adhesion molecule (Lutheran blood group) 0 1 0 1 0 11507772 106 8412 BCAR3 breast cancer anti-estrogen resistance 3 1 0 0 1 0 107 255877 BCL6B B-cell CLL/lymphoma 6, member B (zinc finger protein) 1 0 0 0 0 108 633 BGN biglycan 00010 1 109 23299 BICD2 bicaudal D homolog 2 (Drosophila) 1 0 1 0 0 110 330 BIRC3 baculoviral IAP repeat-containing 3 1 0 0 0 0 111 54739 BIRC4BP XIAP associated factor-1 1 0 0 0 0 112 645 BLVRB biliverdin reductase B (flavin reductase (NADPH)) 0 1 0 0 0 113 650 BMP2 bone morphogenetic protein 2 1 0 0 0 0 114 168667 BMPER BMP binding endothelial regulator 1 0 0 0 0 115 663 BNIP2 BCL2/adenovirus E1B 19kDa interacting protein 2 1 0 0 0 0 116 665 BNIP3L BCL2/adenovirus E1B 19kDa interacting protein 3-like 0 0 0 1 0 117 91653 BOC Boc homolog (mouse) 1 0 0 0 0 118 2186 BPTF bromodomain PHD finger transcription factor 0 1 0 0 0 119 23476 BRD4 bromodomain containing 4 0 1 0 0 0 120 26228 BRDG1 BCR downstream signaling 1 0 0 0 1 0 121 25874 BRP44 brain protein 44 0 1 0 0 0 122 682 BSG basigin (Ok blood group) 0 1 0 0 0 123 9044 BTAF1 BTAF1 RNA polymerase II, B-TFIID transcription factor-associated, 170kDa (Mo 10000 124 689 BTF3 basic transcription factor 3 0 1 0 0 0 125 11067 C10orf10 chromosome 10 open reading frame 10 1 0 0 0 0 126 64115 C10orf54 chromosome 10 open reading frame 54 1 0 0 0 0 127 747 C11orf11 chromosome 11 open reading frame 11 1 1 0 0 0 128 54949 C11orf79 chromosome 11 open reading frame 79 0 1 0 0 0 129 55196 C12orf35 chromosome 12 open reading frame 35 0 0 0 0 1 130 57213 C13orf1 chromosome 13 open reading frame 1 0 1 0 0 0 131 283489 C13orf8 chromosome 13 open reading frame 8 0 0 1 0 0 132 55017 C14orf119 chromosome 14 open reading frame 119 0 1 0 0 0 133 171546 C14orf147 chromosome 14 open reading frame 147 0 1 0 0 0 134 64423 C14orf173 chromosome 14 open reading frame 173 1 0 1 0 0 135 91828 C14orf73 chromosome 14 open reading frame 73 1 0 0 0 0 136 56851 C15orf24 chromosome 15 open reading frame 24 1 0 0 0 0 137 80262 C16orf70 chromosome 16 open reading frame 70 1 0 0 0 0 138 146850 C17orf38 chromosome 17 open reading frame 38 1 0 0 0 0 139 91304 C19orf6 chromosome 19 open reading frame 6 0 1 0 0 0 140 348487 C1orf117 chromosome 1 open reading frame 117 0 0 0 0 1 141 79594 C1orf166 chromosome 1 open reading frame 166 0 1 0 0 0 142 84886 C1orf198 chromosome 1 open reading frame 198 1 0 0 0 0 143 81563 C1orf21 chromosome 1 open reading frame 21 1 0 1 0 0 144 79630 C1orf54 chromosome 1 open reading frame 54 1 0 0 0 0 145 57035 C1orf63 chromosome 1 open reading frame 63 0 0 1 0 0 146 26097 C1orf77 chromosome 1 open reading frame 77 0 1 0 0 0 147 55194 C1orf78 chromosome 1 open reading frame 78 0 0 1 0 0 148 84734 C1orf90 chromosome 1 open reading frame 90 0 0 1 0 0 149 56063 C1orf91 chromosome 1 open reading frame 91 0 1 0 0 0 150 114897 C1QTNF1
Load more

Recommended publications
  • Acetyl Group Coordinated Progression Through the Catalytic Cycle of an Arylalkylamine N-Acetyltransferase
    RESEARCH ARTICLE Acetyl group coordinated progression through the catalytic cycle of an arylalkylamine N-acetyltransferase Adam A. Aboalroub, Ashleigh B. Bachman, Ziming Zhang, Dimitra Keramisanou, David J. Merkler, Ioannis Gelis* Department of Chemistry, University of South Florida, Tampa, Florida, United States of America * [email protected] a1111111111 a1111111111 a1111111111 Abstract a1111111111 a1111111111 The transfer of an acetyl group from acetyl-CoA to an acceptor amine is a ubiquitous bio- chemical transformation catalyzed by Gcn5-related N-acetyltransferases (GNATs). Although it is established that the reaction proceeds through a sequential ordered mecha- nism, the role of the acetyl group in driving the ordered formation of binary and ternary com- OPEN ACCESS plexes remains elusive. Herein, we show that CoA and acetyl-CoA alter the conformation of the substrate binding site of an arylalkylamine N-acetyltransferase (AANAT) to facilitate Citation: Aboalroub AA, Bachman AB, Zhang Z, Keramisanou D, Merkler DJ, Gelis I (2017) Acetyl interaction with acceptor substrates. However, it is the presence of the acetyl group within group coordinated progression through the the catalytic funnel that triggers high affinity binding. Acetyl group occupancy is relayed catalytic cycle of an arylalkylamine N- through a conserved salt bridge between the P-loop and the acceptor binding site, and is acetyltransferase. PLoS ONE 12(5): e0177270. manifested as differential dynamics in the CoA and acetyl-CoA-bound states. The capacity https://doi.org/10.1371/journal.pone.0177270 of the acetyl group carried by an acceptor to promote its tight binding even in the absence of Editor: Viswanathan V. Krishnan, California State CoA, but also its mutually exclusive position to the acetyl group of acetyl-CoA underscore its University Fresno, UNITED STATES importance in coordinating the progression of the catalytic cycle.
    [Show full text]
  • Cloning and Sequence Analysis of Canine Apoptosis-Associated Molecules
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2007 Cloning and sequence analysis of canine apoptosis-associated molecules Schade, Benjamin Abstract: The aim of the study was to clone and sequence the coding sequences of a representative set of proteins, primarily from the intrinsic apoptotic pathway in dogs and to assess their conservation with hu- man and murine orthologues. cDNA for these proteins, including Bcl-2 family members (Bcl-XL, Bcl-w, Mcl-1, Bax, Bak, Bad, Noxa), caspases (Caspase-3, Caspase-8, Caspase-9), Inhibitors of Apoptosis Pro- teins (XIAP, cIAP-1, cIAP-2, Survivin), their mitochondrial inhibitors (Smac/ DIABLO, Omi/HtrA2) and p53, were generated by RT-PCR with RNA extracted from two canine non-neoplastic cell lines. Eleven sequences are novel for the dog. Interspecies comparison revealed strongest similarity between the sequences of human and canine intrinsic apoptosis pathway members. Differences with potential func- tional impact, however, were observed in both dogs and mice. In dogs, these changes involve the putative Inhibitor of Apoptosis Protein binding motif of canine Omi/HtrA2, some caspase substrate recognition motifs and some functionally relevant residues of p53. Canine XIAP yields a caspase-cleavage site reported as unique to humans. In conclusion, the generally high degree of similarity of canine apoptosis-associated proteins as compared to human counterparts is supportive of the use of dogs as a model for human dis- eases. Single interspecies sequence variations with potential functional relevance under physiologic and neoplastic conditions do exist, however, and will require further analysis.
    [Show full text]
  • Supplementary Materials For
    Supplementary Materials for Elucidating cellular population dynamics by molecular density function perturbations 1 2,3, Thanneer Malai Perumal ​ and Rudiyanto Gunawan *​ ​ ​ 1 Sage Bionetworks, Seattle, Washington, USA; [email protected] 2 Institute for Chemical and Bioengineering, ETH Zurich, Zurich, Switzerland; [email protected] 3 Swiss Institute of Bioinformatics, Lausanne, Switzerland * Correspondence: [email protected]; Tel.: +41-44-633-2134 Supplementary Material S1. Probability Distance Metrics Signed Engineering Metric: ∞ 2 ∆ (f A (t, x )||f B (t, x )) = sign(∆μ ) ∫ (x f A (t, x ) − x f B (t, x )) dx (S. 1) E Xi i Xi i Xi i Xi i i Xi i i −∞ Signed Jeffrey Divergence: ∞ f A (t,x ) A B A B Xi i ∆ (f (t, x )||f (t, x )) = sgn(∆μ ) ∫ (f (t, x ) − f (t, x ))ln ( B ) )dx (S. 2) JD Xi i Xi i Xi Xi i Xi i f (t,x ) i −∞ Xi i Signed Kullback-Leibler Distance: ∞ f B (t,x ) A B B Xi i ∆ (f (t, x )||f (t, x )) = sgn(∆μ ) ∫ f (t, x )ln ( A ) dx (S. 3) KLD Xi i Xi i Xi Xi i f (t,x ) i −∞ Xi i Signed Jensen-Shannon Divergence: f + (t,x )+f − (t,x ) Xi i Xi i ∆ f (t, x ) = sgn(∆μ ) (S. 4) JSD Xi i Xi 2 Signed Kolmogorov-Smirnov Metric: ∆ (f A (t, x )||f B (t, x )) = sgn(∆μ )sup|F A (t, x ) − F B (t, x )| (S. 5) KS Xi i Xi i Xi Xi i Xi i Supplementary Material S2.
    [Show full text]
  • Comparison of Gene Expression Profiles in Chromate Transformed BEAS-2B Cells
    Comparison of Gene Expression Profiles in Chromate Transformed BEAS-2B Cells Hong Sun1, Harriet A. Clancy1, Thomas Kluz1, Jiri Zavadil2, Max Costa1* 1 Nelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, New York, United States of America, 2 Department of Pathology, NYU Cancer Institute and Center for Health Informatics and Bioinformatics, NYU Langone Medical Center, New York, New York, United States of America Abstract Background: Hexavalent chromium [Cr(VI)] is a potent human carcinogen. Occupational exposure has been associated with increased risk of respiratory cancer. Multiple mechanisms have been shown to contribute to Cr(VI) induced carcinogenesis, including DNA damage, genomic instability, and epigenetic modulation, however, the molecular mechanism and downstream genes mediating chromium’s carcinogenicity remain to be elucidated. Methods/Results: We established chromate transformed cell lines by chronic exposure of normal human bronchial epithelial BEAS-2B cells to low doses of Cr(VI) followed by anchorage-independent growth. These transformed cell lines not only exhibited consistent morphological changes but also acquired altered and distinct gene expression patterns compared with normal BEAS-2B cells and control cell lines (untreated) that arose spontaneously in soft agar. Interestingly, the gene expression profiles of six Cr(VI) transformed cell lines were remarkably similar to each other yet differed significantly from that of either control cell lines or normal BEAS-2B cells. A total of 409 differentially expressed genes were identified in Cr(VI) transformed cells compared to control cells. Genes related to cell-to-cell junction were upregulated in all Cr(VI) transformed cells, while genes associated with the interaction between cells and their extracellular matrices were down-regulated.
    [Show full text]
  • ANKRD11 Gene Ankyrin Repeat Domain 11
    ANKRD11 gene ankyrin repeat domain 11 Normal Function The ANKRD11 gene provides instructions for making a protein called ankyrin repeat domain 11 (ANKRD11). As its name suggests, this protein contains multiple regions called ankyrin domains; proteins with these domains help other proteins interact with each other. The ANKRD11 protein interacts with certain proteins called histone deacetylases, which are important for controlling gene activity. Through these interactions, ANKRD11 affects when genes are turned on and off. For example, ANKRD11 brings together histone deacetylases and other proteins called p160 coactivators. This association regulates the ability of p160 coactivators to turn on gene activity. ANKRD11 may also enhance the activity of a protein called p53, which controls the growth and division (proliferation) and the self-destruction (apoptosis) of cells. The ANKRD11 protein is found in nerve cells (neurons) in the brain. During embryonic development, ANKRD11 helps regulate the proliferation of these cells and development of the brain. Researchers speculate that the protein may also be involved in the ability of neurons to change and adapt over time (plasticity), which is important for learning and memory. ANKRD11 may function in other cells in the body and appears to be involved in normal bone development. Health Conditions Related to Genetic Changes KBG syndrome Several ANKRD11 gene mutations have been found to cause KBG syndrome, a condition characterized by large upper front teeth and other unusual facial features, skeletal abnormalities, and intellectual disability. Most of these mutations lead to an abnormally short ANKRD11 protein, which likely has little or no function. Reduction of this protein's function is thought to underlie the signs and symptoms of the condition.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Downloaded from [266]
    Patterns of DNA methylation on the human X chromosome and use in analyzing X-chromosome inactivation by Allison Marie Cotton B.Sc., The University of Guelph, 2005 A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY in The Faculty of Graduate Studies (Medical Genetics) THE UNIVERSITY OF BRITISH COLUMBIA (Vancouver) January 2012 © Allison Marie Cotton, 2012 Abstract The process of X-chromosome inactivation achieves dosage compensation between mammalian males and females. In females one X chromosome is transcriptionally silenced through a variety of epigenetic modifications including DNA methylation. Most X-linked genes are subject to X-chromosome inactivation and only expressed from the active X chromosome. On the inactive X chromosome, the CpG island promoters of genes subject to X-chromosome inactivation are methylated in their promoter regions, while genes which escape from X- chromosome inactivation have unmethylated CpG island promoters on both the active and inactive X chromosomes. The first objective of this thesis was to determine if the DNA methylation of CpG island promoters could be used to accurately predict X chromosome inactivation status. The second objective was to use DNA methylation to predict X-chromosome inactivation status in a variety of tissues. A comparison of blood, muscle, kidney and neural tissues revealed tissue-specific X-chromosome inactivation, in which 12% of genes escaped from X-chromosome inactivation in some, but not all, tissues. X-linked DNA methylation analysis of placental tissues predicted four times higher escape from X-chromosome inactivation than in any other tissue. Despite the hypomethylation of repetitive elements on both the X chromosome and the autosomes, no changes were detected in the frequency or intensity of placental Cot-1 holes.
    [Show full text]
  • Molecular and Cellular Mechanisms of the Angiogenic Effect of Poly(Methacrylic Acid-Co-Methyl Methacrylate) Beads
    Molecular and Cellular Mechanisms of the Angiogenic Effect of Poly(methacrylic acid-co-methyl methacrylate) Beads by Lindsay Elizabeth Fitzpatrick A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Institute of Biomaterials and Biomedical Engineering University of Toronto © Copyright by Lindsay Elizabeth Fitzpatrick 2012 Molecular and Cellular Mechanisms of the Angiogenic Effect of Poly(methacrylic acid-co-methyl methacrylate) Beads Lindsay Elizabeth Fitzpatrick Doctorate of Philosophy Institute of Biomaterials and Biomedical Engineering University of Toronto 2012 Abstract Poly(methacrylic acid -co- methyl methacrylate) beads were previously shown to have a therapeutic effect on wound closure through the promotion of angiogenesis. However, it was unclear how this polymer elicited its beneficial properties. The goal of this thesis was to characterize the host response to MAA beads by identifying molecules of interest involved in MAA-mediated angiogenesis (in comparison to poly(methyl methacrylate) beads, PMMA). Using a model of diabetic wound healing and a macrophage-like cell line (dTHP-1), eight molecules of interest were identified in the host response to MAA beads. Gene and/or protein expression analysis showed that MAA beads increased the expression of Shh, IL-1β, IL-6, TNF- α and Spry2, but decreased the expression of CXCL10 and CXCL12, compared to PMMA and no beads. MAA beads also appeared to modulate the expression of OPN. In vivo, the global gene expression of OPN was increased in wounds treated with MAA beads, compared to PMMA and no beads. In contrast, dTHP-1 decreased OPN gene expression compared to PMMA and no beads, but expressed the same amount of secreted OPN, suggesting that the cells decreased the expression of the intracellular isoform of OPN.
    [Show full text]
  • Supp Table 1.Pdf
    Upregulated genes in Hdac8 null cranial neural crest cells fold change Gene Symbol Gene Title 134.39 Stmn4 stathmin-like 4 46.05 Lhx1 LIM homeobox protein 1 31.45 Lect2 leukocyte cell-derived chemotaxin 2 31.09 Zfp108 zinc finger protein 108 27.74 0710007G10Rik RIKEN cDNA 0710007G10 gene 26.31 1700019O17Rik RIKEN cDNA 1700019O17 gene 25.72 Cyb561 Cytochrome b-561 25.35 Tsc22d1 TSC22 domain family, member 1 25.27 4921513I08Rik RIKEN cDNA 4921513I08 gene 24.58 Ofa oncofetal antigen 24.47 B230112I24Rik RIKEN cDNA B230112I24 gene 23.86 Uty ubiquitously transcribed tetratricopeptide repeat gene, Y chromosome 22.84 D8Ertd268e DNA segment, Chr 8, ERATO Doi 268, expressed 19.78 Dag1 Dystroglycan 1 19.74 Pkn1 protein kinase N1 18.64 Cts8 cathepsin 8 18.23 1500012D20Rik RIKEN cDNA 1500012D20 gene 18.09 Slc43a2 solute carrier family 43, member 2 17.17 Pcm1 Pericentriolar material 1 17.17 Prg2 proteoglycan 2, bone marrow 17.11 LOC671579 hypothetical protein LOC671579 17.11 Slco1a5 solute carrier organic anion transporter family, member 1a5 17.02 Fbxl7 F-box and leucine-rich repeat protein 7 17.02 Kcns2 K+ voltage-gated channel, subfamily S, 2 16.93 AW493845 Expressed sequence AW493845 16.12 1600014K23Rik RIKEN cDNA 1600014K23 gene 15.71 Cst8 cystatin 8 (cystatin-related epididymal spermatogenic) 15.68 4922502D21Rik RIKEN cDNA 4922502D21 gene 15.32 2810011L19Rik RIKEN cDNA 2810011L19 gene 15.08 Btbd9 BTB (POZ) domain containing 9 14.77 Hoxa11os homeo box A11, opposite strand transcript 14.74 Obp1a odorant binding protein Ia 14.72 ORF28 open reading
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0264.634 A1 Amersdorfer Et Al
    US 20120264.634A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0264.634 A1 Amersdorfer et al. (43) Pub. Date: Oct. 18, 2012 (54) MARKER SEQUENCES FOR PANCREATIC Publication Classification CANCER DISEASES, PANCREATIC (51) Int. Cl. CARCINOMIA AND USE THEREOF C40B 30/04 (2006.01) GOIN 2L/64 (2006.01) (75) Inventors: Peter Amersdorfer, Graz (AT); GOIN 27/72 (2006.01) Annabel Höpfner, Dortmund (DE); C07K I4/435 (2006.01) Angelika Lueking, Bochum (DE) C40B 40/06 (2006.01) C40B 40/10 (2006.01) CI2N 5/09 (2010.01) (73) Assignee: PROTAGEN Aktiengesellschaft, C7H 2L/04 (2006.01) Dortmund (DE) GOIN 33/574 (2006.01) GOIN 27/62 (2006.01) (21) Appl. No.: 13/498,964 (52) U.S. Cl. ........... 506/9:436/501; 435/6.14; 435/7.92; 506/16:506/18: 435/2:536/23.1; 530/350 (22) PCT Filed: Sep. 29, 2010 (57) ABSTRACT The present invention relates to novel marker sequences for (86). PCT No.: PCT/EP2010/064510 pancreatic cancer diseases, pancreatic carcinoma and the diagnostic use thereof together with a method for Screening of S371 (c)(1), potential active Substances for pancreatic cancer diseases, (2), (4) Date: Jun. 22, 2012 pancreatic carcinoma by means of these marker sequences. Furthermore, the invention relates to a diagnostic device con (30) Foreign Application Priority Data taining Such marker sequences for pancreatic cancer diseases, pancreatic carcinoma, in particular a protein biochip and the Sep. 29, 2009 (EP) .................................. O9171690.2 use thereof. Patent Application Publication Oct. 18, 2012 US 2012/0264.634 A1 US 2012/0264.634 A1 Oct.
    [Show full text]
  • Fine Mapping Studies of Quantitative Trait Loci for Baseline Platelet Count in Mice and Humans
    Fine mapping studies of quantitative trait loci for baseline platelet count in mice and humans A thesis submitted in fulfillment of the requirements for the degree of Doctor of Philosophy Melody C Caramins December 2010 University of New South Wales ORIGINALITY STATEMENT ‘I hereby declare that this submission is my own work and to the best of my knowledge it contains no materials previously published or written by another person, or substantial proportions of material which have been accepted for the award of any other degree or diploma at UNSW or any other educational institution, except where due acknowledgement is made in the thesis. Any contribution made to the research by others, with whom I have worked at UNSW or elsewhere, is explicitly acknowledged in the thesis. I also declare that the intellectual content of this thesis is the product of my own work, except to the extent that assistance from others in the project's design and conception or in style, presentation and linguistic expression is acknowledged.’ Signed …………………………………………….............. Date …………………………………………….............. This thesis is dedicated to my father. Dad, thanks for the genes – and the environment! ACKNOWLEDGEMENTS “Nothing can come out of nothing, any more than a thing can go back to nothing.” - Marcus Aurelius Antoninus A PhD thesis is never the work of one person in isolation from the world at large. I would like to thank the following people, without whom this work would not have existed. Thank you firstly, to all my teachers, of which there have been many. Undoubtedly, the greatest debt is owed to my supervisor, Dr Michael Buckley.
    [Show full text]
  • Cellular and Molecular Signatures in the Disease Tissue of Early
    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
    [Show full text]